cbdMD, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.4M
- Price
- $0.3948
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.00%
- Volume
- 74.0K
About
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
Quick stats
Shares outstanding11.2M
Computed float11.1M
Float / shares98.9%
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001644903
Websitehttps://www.cbdmd.com
AI Summary
AI-generated1/17
minorneutralproduct launch
Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation
Reserveage, part of the Twinlab family of brands, launched Longev+, a healthy-aging supplement combining amino acids, HMB, creatine and resveratrol, available exclusively at The Vitamin Shoppe in a 20-count Mixed Berry stick-pack format.
The launch is relevant to cbdMD (YCBD) because Reserveage is among the Twinlab brands included in cbdMD's previously announced definitive asset purchase agreement, which remains subject to court approval and customary closing conditions.
For YCBD the event is indirect: it supports the strategic rationale cited by cbdMD management for the Twinlab deal, but no financial figures or deal terms were disclosed in the release.
Red flags
- proposed Twinlab acquisition still requires court approval (ABC process) and unaudited/acquired-brand financial information may not meet Regulation S-X requirements